TherapeuticsMD Inc (NYSEMKT:TXMD) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Friday.

A number of other analysts also recently commented on TXMD. Oppenheimer Holdings, Inc. upgraded TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. Morgan Stanley began coverage on TherapeuticsMD in a research report on Friday, September 8th. They set an “equal weight” rating and a $6.00 price target on the stock. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price target on shares of TherapeuticsMD in a research report on Thursday, May 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $18.93.

Shares of TherapeuticsMD (TXMD) traded up 1.23% during mid-day trading on Friday, reaching $6.60. The company had a trading volume of 3,198,787 shares. The company’s market capitalization is $1.35 billion. The stock has a 50 day moving average of $5.97 and a 200-day moving average of $5.59. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30.

COPYRIGHT VIOLATION WARNING: “TherapeuticsMD Inc (TXMD) Downgraded by BidaskClub” was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/16/therapeuticsmd-inc-txmd-downgraded-by-bidaskclub.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.